F
688221
vs
S
Shanghai Composite
Over the past 12 months, Frontier Biotechnologies Inc has significantly outperformed Shanghai Composite, delivering a return of +122% compared to the Shanghai Composite's +24% growth.
Stocks Performance
688221 vs Shanghai Composite
Performance Gap
688221 vs Shanghai Composite
Performance By Year
688221 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Frontier Biotechnologies Inc
Glance View
Frontier Biotechnologies, Inc. engages in the research and development, production, and sale of medicines. The company is headquartered in Nanjing, Jiangsu and currently employs 495 full-time employees. The company went IPO on 2020-10-28. The firm's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The firm conducts its businesses within the China market and to overseas markets.